Clinical Commissioning Policy: Addition of rituximab to first-line standard chemotherapy for CD20 positive B-cell precursor acute lymphoblastic leukaemia (Adults)
The addition of rituximab to first-line standard chemotherapy is now recommended as a treatment option through routine commissioning for CD20 positive B-cell precursor acute lymphoblastic leukaemia within the criteria set out in this document.
Source:
NHS England